Rahul Chopra, MD
Radiation Oncology · Melbourne, FLNPI 1962665877
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,191 of the $12,291 with a category attached, or 82.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,335 and has fallen 64.3% since, to $1,548 in 2025. Among radiation oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $36.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novocure Inc.$917
- Merck$677
- Johnson & Johnson$561
- Novartis$548
- E.r. Squibb & Sons, L.L.C.$487
- plus $6K from 54 others
What the payments were for
- Consulting fees$2,10017%
- Food & beverage$10,19183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,291 in reported general payments places this provider in the 90th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 28 | $366 |
| Tamsulosin Hcl | 23 | $213 |
| Ondansetron Hcl | 11 | $120 |
| SsdSilver Sulfadiazine | 12 | $112 |
| Ciprofloxacin Hcl | 24 | $101 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Melbourne
- Fe PancitoMelbourne$18K
- James GiebinkMelbourne$10K
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.